DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/thgz9g/protein) has announced the addition of the "Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017" report to their offering.
Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications.
The global protein engineering technologies market (2012-2017) report analyses the market by technology, products, applications, and geography. It also includes recent technology trends, patents, and funding analysis. In addition, it also covers factors driving and restraining the growth of the market and market scenario in the U.S., Europe, Asia, and Rest of the World (RoW).
The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. However, development costs, stringent regulatory issues, and risk of failure of the drug in the testing phase restraints the growth of the market. Further, the availability of generics and patent infringements is posing a threat to the market.
This technical report categorizes the market for protein engineering by geography, applications, products, and technology, forecasting the market revenue by analyzing current and future trends in therapeutics and diagnostics.These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.
Key Topics Covered:
2 Executive Summary
3 Protein Engineering Technologies - Landscape Analysis
5 Market Landscape Analysis
6 Geographic Analysis
7 Technology And Product Portfolio
8 Competitive Landscape
9 Analyst Insights And Recommendation
10 Company Profiles
- Amgen, Inc.
- Avidbiotics Corp. (U.S.)
- Biogen Idec, Inc.
- Bristol Myers Squibb Co.
- Dna2.0, Inc. (U.S.)
- Eleven Biotherapeutics (U.S.)
- Eli Lilly & Co
- Genentech, Inc.
- Glaxo Smithkline Plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis Ag
- Pfizer, Inc.
- Regeneron Pharmaceuticals, Inc.
- Sigma-Aldrich Corp. (U.S.)
- Toolgen, Inc. (Korea)
- Xencor Inc.
For more information visit http://www.researchandmarkets.com/research/thgz9g/protein